HOME >> BIOLOGY >> NEWS
Tumor cell-specific therapy shows preclinical promise

Cancer often begins with mutations in tumor suppressor pathways. Tumor suppressor genes--such as p53--arrest cell growth and induce apoptosis (programmed cell death) in response to cellular stress, such as chromosomal damage. Cells with p53 mutations can escape these constraints, leading to the uncontrolled growth characteristic of "immortal" cancer cells. Nearly all types of tumors have mutations in the p53 pathway, many of them in the p53 gene itself. Treatments focused on restoring p53 function--which is lost selectively in cancer cells--should prove more effective than standard therapies which indiscriminately target all dividing cells. With the goal of developing specific therapeutic strategies, Steven Dowdy and colleagues show that restoring p53 protein function in mouse cancer models eliminates tumors and dramatically increases survival of the animals.

While past efforts to restore tumor suppressor function in cancer cells have focused on gene therapy, Dowdy and colleagues introduced modified p53 peptides (parts of the protein) into cancer cells. p53 works as a "transcriptional" activator that binds to specific gene sequences and triggers apoptosis in response to DNA damage. One region of the p53 protein, the C-terminal domain, facilitates DNA binding. In cancer cells, synthesized peptides (called p53C) derived from this region can induce apoptosis by restoring function to p53 proteins with DNA-binding mutations.

To get p53C peptides into cancer cells, the scientists used a technique pioneered by Dowdy that delivers proteins into the cell interior. Since the cell membrane normally limits passage to only small molecules (larger molecules generally enter through surface receptors), this is no small feat. Testing the effectiveness of the peptide therapy on mouse strains that model human metastatic disease, the scientists found that mice treated with the p53C peptide showed a significant reduction in tumor mass and lived six times longer than mi
'"/>

Contact: Barbara Cohen
bcohen@plos.org
415-624-1206
Public Library of Science
17-Feb-2004


Page: 1 2

Related biology news :

1. Tumor cells made more sensitive to radiation by blocking a key cellular molecule
2. Discovery Of 13 Genes Expressed In Brain Tumors May Lead To More Effective Diagnosis Or Prevention
3. Dietary Lutein Inhibits Mammary Tumor Growth And Normalizes Immune Balance In Tumor-Bearing Mice
4. Tumor Oxygen Level And Blood Flow Fluctuate, Duke Scientists Discover
5. Vion Demonstrates Readiness Of First Tumor-Targeting Salmonella For Human Testing Against Solid Tumors
6. Compounds From Fruits, Vegetables And Grains Slow The Growth Of Human Tumor Cells
7. New Cell Isolation Method Will Aid In Studying Tumor Development
8. Wistar Institute To Host 3rd International Conference On Molecular And Clinical Genetics Of Childhood Renal Tumors And The Mitchell Ross Symposium
9. Scientists Study Proteins Role In Tumor Development In Fish
10. Fly Tumor Points Way To New Understanding Of Cancer Development
11. Vions TAPET Organisms Demonstrate Reduced Virulence, Increased Safety While Retaining Ability To Specifically Target Tumors

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/26/2019)... , ... October 23, 2019 , ... ... Christina Hughes , to its executive leadership team. , As a market ... solutions allow growth-stage biotech and pharma companies to reduce timelines and improve quality ...
(Date:10/26/2019)... ... October 25, 2019 , ... ... built, helium-based leak testing instruments for the Pharmaceutical, Biotechnology, Medical Device and Food ... advanced helium leak detection system, the SIMS Model 1915+ . The SIMS ...
(Date:10/22/2019)... ... ... Greenberg Traurig, LLP’s global Life Sciences & Medical Technology Group ... Sector,” with German biotech strategy consulting firm, Catenion. The seminar will take place from ... . , Speakers from Greenberg Traurig and Catenion will discuss best practices and practical ...
Breaking Biology News(10 mins):
(Date:11/9/2019)... ... November 08, 2019 , ... ... intelligence (AI)-powered technology for use in pathology research, today announced the results ... samples from patients enrolled in the phase 3 selonsertib studies (STELLAR). Strong ...
(Date:11/5/2019)... ... November 05, 2019 , ... ... has received CE Mark for its Fusion Bx 2.0 prostate fusion biopsy solution. ... interface, the Fusion Bx 2.0 will give urologists across Europe the ability to ...
(Date:11/2/2019)... ... October 31, 2019 , ... ... artificial intelligence pioneer tellic. drug360 brings tellic’s expertise in biomedical language processing ... researchers to quickly uncover relationships between genes, diseases, variants, phenotypes, and other biomedical ...
(Date:10/29/2019)... ... October 29, 2019 , ... ... to announce its Silver sponsorship and cold chain validation workshop at the Biomanufacturing ... Pines in San Diego, California. , The Biomanufacturing World Summit brings ...
Breaking Biology Technology:
Cached News: